(Reuters) -The U.S. Food and Drug Administration has approved Novartis’ oral treatment for patients with type of chronic inflammatory skin disease, the company said on Tuesday.
The twice-daily pill, Rhapsido, is approved for patients who have symptoms of chronic spontaneous urticaria (CSU) despite standard therapies.
CSU is a long-term skin condition without a known cause, characterized by recurring hives – itchy, red welts – and sometimes swelling, lasting six weeks or more.
Novartis has completed regulatory submissions in the European Union and Japan, and a priority review has been granted in China, it said.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Sahal Muhammed)
Brought to you by www.srnnews.com
